Matches in Ghent University Academic Bibliography for { <https://biblio.ugent.be/publication/01H3CM7GE51A9FAM9NRFQYQ05E> ?p ?o. }
Showing items 1 to 26 of
26
with 100 items per page.
- 01H3CM7GE51A9FAM9NRFQYQ05E classification A1.
- 01H3CM7GE51A9FAM9NRFQYQ05E date "2023".
- 01H3CM7GE51A9FAM9NRFQYQ05E language "eng".
- 01H3CM7GE51A9FAM9NRFQYQ05E type journalArticle.
- 01H3CM7GE51A9FAM9NRFQYQ05E hasPart 01H3CM7R2WSB6KR1DTHGQ3E064.pdf.
- 01H3CM7GE51A9FAM9NRFQYQ05E subject "Biology and Life Sciences".
- 01H3CM7GE51A9FAM9NRFQYQ05E doi "10.1371/journal.pone.0280825".
- 01H3CM7GE51A9FAM9NRFQYQ05E issn "1932-6203".
- 01H3CM7GE51A9FAM9NRFQYQ05E issue "1".
- 01H3CM7GE51A9FAM9NRFQYQ05E volume "18".
- 01H3CM7GE51A9FAM9NRFQYQ05E abstract "Influenza B viruses (IBV) are responsible for a considerable part of the burden caused by influenza virus infections. Since their emergence in the 1980s, the Yamagata and Victoria antigenic lineages of influenza B circulate in alternate patterns across the globe. Furthermore, their evolutionary divergence and the appearance of new IBV subclades complicates the prediction of future influenza vaccines compositions. It has been proposed that the addition of the neuraminidase (NA) antigen could potentially induce a broader protection and compensate for hemagglutinin (HA) mismatches in the current vaccines. Here we show that anti-NA and -HA sera against both Victoria and Yamagata lineages have limited inter-lineage cross-reactivity. When transferred to mice prior to infection with a panel of IBVs, anti-NA sera were as potent as anti-HA sera in conferring protection against homologous challenge and, in some cases, conferred superior protection against challenge with heterologous IBV strains.".
- 01H3CM7GE51A9FAM9NRFQYQ05E author EE838BEC-6333-11E6-AF4E-6122B5D1D7B1.
- 01H3CM7GE51A9FAM9NRFQYQ05E author F48175CA-F0ED-11E1-A9DE-61C894A0A6B4.
- 01H3CM7GE51A9FAM9NRFQYQ05E author F9C79578-F0ED-11E1-A9DE-61C894A0A6B4.
- 01H3CM7GE51A9FAM9NRFQYQ05E author FB640EE8-F0ED-11E1-A9DE-61C894A0A6B4.
- 01H3CM7GE51A9FAM9NRFQYQ05E author urn:uuid:1b442a2e-4c6c-4e94-a5e9-b3af3f577c7b.
- 01H3CM7GE51A9FAM9NRFQYQ05E author urn:uuid:33d96470-2590-485a-97ff-62ea2ab0d76c.
- 01H3CM7GE51A9FAM9NRFQYQ05E dateCreated "2023-06-20T14:44:36Z".
- 01H3CM7GE51A9FAM9NRFQYQ05E dateModified "2024-12-12T17:55:44Z".
- 01H3CM7GE51A9FAM9NRFQYQ05E editor urn:uuid:f2acff96-6cb8-4cb5-a17d-0aa850dc5d55.
- 01H3CM7GE51A9FAM9NRFQYQ05E name "Anti-neuraminidase and anti-hemagglutinin immune serum can confer inter-lineage cross protection against recent influenza B".
- 01H3CM7GE51A9FAM9NRFQYQ05E pagination urn:uuid:0c636252-7c5c-4401-8512-48d6b027b467.
- 01H3CM7GE51A9FAM9NRFQYQ05E sameAs LU-01H3CM7GE51A9FAM9NRFQYQ05E.
- 01H3CM7GE51A9FAM9NRFQYQ05E sourceOrganization urn:uuid:7280ae06-8e95-4e25-8218-05e1755a8a27.
- 01H3CM7GE51A9FAM9NRFQYQ05E sourceOrganization urn:uuid:73bd8bec-cdfe-4422-906c-3a0a67f4776e.
- 01H3CM7GE51A9FAM9NRFQYQ05E type A1.